Levodopa/Carbidopa (Contera Pharma)

N/A

Report date: 2025/03/12 16:24:43

Base Information

Drug NameLevodopa/Carbidopa (Contera Pharma)
Drug Alias NameJM-012CP-012SOL-707
ClassificationSmall molecules
Mechanisms of ActionDOPA decarboxylase inhibitorsDopamine receptors agonists
TargetsAromatic-L-amino-acid decarboxylaseDopamine receptors
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesContera Pharma
China Registration ClassN/A

Develop Information

Active CompaniesBdd PharmaContera Pharma
Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A